1. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
- Author
-
Gary Frey, Tianshu Xiao, Bing Chen, David A. Scott, Michael S. Seaman, Christy L. Lavine, Qingshan Fu, and James J. Chou
- Subjects
Magnetic Resonance Spectroscopy ,Viral protein ,Anti-HIV Agents ,Drug Evaluation, Preclinical ,Fluorescence Polarization ,Drug resistance ,medicine.disease_cause ,Article ,Small Molecule Libraries ,03 medical and health sciences ,Structure-Activity Relationship ,medicine ,Structure–activity relationship ,Humans ,Binding site ,Neutralizing antibody ,Molecular Biology ,030304 developmental biology ,0303 health sciences ,Mutation ,Binding Sites ,biology ,Molecular Structure ,Chemistry ,030302 biochemistry & molecular biology ,HEK 293 cells ,Cell Membrane ,Lipid bilayer fusion ,Cell Biology ,Surface Plasmon Resonance ,Virus Internalization ,HIV Envelope Protein gp41 ,Cell biology ,HEK293 Cells ,Dequalinium ,CD4 Antigens ,biology.protein ,HIV-1 ,Hydrophobic and Hydrophilic Interactions - Abstract
Combination antiretroviral therapy has transformed HIV-1 infection, once a fatal illness, into a manageable chronic condition. Drug resistance, severe side effects and treatment noncompliance bring challenges to combination antiretroviral therapy implementation in clinical settings and indicate the need for additional molecular targets. Here, we have identified several small-molecule fusion inhibitors, guided by a neutralizing antibody, against an extensively studied vaccine target-the membrane proximal external region (MPER) of the HIV-1 envelope spike. These compounds specifically inhibit the HIV-1 envelope-mediated membrane fusion by blocking CD4-induced conformational changes. An NMR structure of one compound complexed with a trimeric MPER construct reveals that the compound partially inserts into a hydrophobic pocket formed exclusively by the MPER residues, thereby stabilizing its prefusion conformation. These results suggest that the MPER is a potential therapeutic target for developing fusion inhibitors and that strategies employing an antibody-guided search for novel therapeutics may be applied to other human diseases.
- Published
- 2020